An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)

Trial Profile

An Open Label, Active Comparator Extension Trial to Assess the Effect of Long Term Dosing of Inclisiran and Evolocumab Given as Subcutaneous Injections in Participants With High Cardiovascular Risk and Elevated LDL-C (ORION-3)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Mar 2018

At a glance

  • Drugs Inclisiran (Primary) ; Evolocumab
  • Indications Hypercholesterolaemia
  • Focus Therapeutic Use
  • Acronyms ORION-3
  • Sponsors The Medicines Company
  • Most Recent Events

    • 20 Dec 2017 Planned End Date changed from 1 Jun 2021 to 1 Jan 2022.
    • 20 Dec 2017 Planned primary completion date changed from 1 Jan 2018 to 1 Aug 2018.
    • 20 Dec 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top